Collectively, these data suggest that single-agent administration with PLK4 inhibitor CFI-400945 may be a promising therapeutic strategy to overcome oxaliplatin-involved chemoresistance in colorectal cancer. This evidence concerns the gene PLK4 and colorectal cancer.